AUS
NZ
UK
CA
USA
IND
Highlights
- Oncolytics Biotech Inc. shares recently surpassed their 200-day moving average.
- The company focuses on developing treatments for cancer, with its lead product in phase 3 clinical trials.
- Key financial metrics include a significant market capitalization and a notable debt-to-equity ratio.
Oncolytics Biotech Inc. (TSX:ONC) operates within the biopharmaceutical sector, concentrating on the discovery and development of innovative cancer treatments. The company's primary focus is on pelareorep, an intravenously delivered immunotherapeutic agent. This agent is currently in phase 3 clinical trials for treating hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.
Recent Stock Performance
During recent trading, Oncolytics Biotech Inc. shares moved above their 200-day moving average. The stock's 200-day moving average is C$1.40, and it traded as high as C$1.42. The shares last traded at C$1.41, with a trading volume of 199,488 shares.
Financial Metrics
The company has a significant market capitalization. Its price-to-earnings ratio stands at a negative value, and it has a beta indicating its volatility. Oncolytics Biotech Inc. maintains a notable debt-to-equity ratio, a high quick ratio, and a strong current ratio. The 50-day simple moving average for the stock is C$1.43, while the 200-day simple moving average is C$1.40.
Oncolytics Biotech Inc. is a clinical-stage biopharmaceutical company dedicated to developing pharmaceutical products for cancer treatment. The company's lead product, pelareorep, is an intravenously delivered immunotherapeutic agent. It is currently in phase 3 clinical trials for treating hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.
This article provides an overview of Oncolytics Biotech Inc., highlighting its recent stock performance and key financial metrics. The company's focus on developing innovative cancer treatments positions it as a significant player in the biopharmaceutical sector.
